Umlahlankosi

Cissus quadrangularis contains phytosterols (β-sitosterol, ketosetosterol), resveratrol-class stilbenes (quadrangularin-A, piceatannol), and triterpenoids (friedelin, lupeol) that collectively modulate NF-κB signaling, cyclooxygenase enzymes, and osteoblast activity to accelerate fracture repair and reduce inflammation. Preclinical studies and limited human trials demonstrate accelerated radiological bone healing and clinically significant reductions in pain and swelling in fracture patients treated with standardized extracts, with one controlled trial reporting healing times reduced by approximately 33% compared to controls.

Origin & History

Cissus quadrangularis is a perennial succulent vine native to tropical and subtropical regions of Africa, South Asia, and Southeast Asia, growing particularly abundantly across sub-Saharan Africa, India, and Sri Lanka. In southern Africa, it thrives in hot, dry bushveld and rocky terrain, where the Zulu people harvest its quadrangular stems for medicinal use. The plant is drought-tolerant, grows rapidly as a climbing vine using tendrils, and has been cultivated informally around homesteads for generations due to its recognized medicinal properties.

Historical & Cultural Context

Among the Zulu people of southern Africa, Cissus quadrangularis—known as Umlahlankosi, meaning approximately 'that which reunites bones'—has been used for centuries as the primary botanical remedy for fractures, dislocations, and joint injuries, with healers applying macerated stem material directly to the fracture site as a poultice or administering it orally as a decoction. In the Ayurvedic system of South Asia, the plant is recorded as Asthisamharaka (Sanskrit: 'that which prevents the destruction of bone') or Hadjod, and is listed in classical texts including the Sushruta Samhita for the treatment of fractures, rheumatism, and digestive disorders. Traditional preparers in both African and South Asian contexts valued the plant's quadrangular succulent stems, which were split, roasted, or ground into paste and applied with oil or ghee, reflecting an empirical recognition of its anti-inflammatory and bone-restorative properties long before phytochemical characterization. The plant's use across geographically distant traditional medicine systems—Unani, Siddha, Ayurvedic, and multiple African ethnomedicinal traditions—independently converging on bone and joint applications represents one of the stronger cases of cross-cultural ethnopharmacological validation in this class of medicinal plants.

Health Benefits

- **Bone Fracture Healing**: Phytosterols, particularly β-sitosterol and ketosetosterol, are believed to stimulate osteoblast proliferation and collagen synthesis, while ascorbic acid supports hydroxylation of procollagen, collectively accelerating callus formation and radiological bone healing in fracture patients.
- **Anti-Inflammatory Activity**: Acetone extracts inhibit cyclooxygenase-1 (IC₅₀ ~7 µg/ml) and cyclooxygenase-2 (IC₅₀ ~0.4 µg/ml), and 5-lipoxygenase (IC₅₀ ~20 µg/ml), suppressing prostaglandin and leukotriene synthesis to reduce pain and tissue swelling associated with musculoskeletal injury.
- **Antioxidant Protection**: Ethanolic extracts scavenge DPPH, superoxide, and hydroxyl free radicals while upregulating endogenous antioxidant enzymes—superoxide dismutase and glutathione peroxidase—providing cellular protection against oxidative stress in injured or inflamed tissues.
- **Gastroprotective Effects**: Stem extracts have demonstrated protective activity against aspirin-induced gastric mucosal damage in preclinical models, attributed to tannins and phenolic compounds that reinforce the mucous barrier and reduce oxidative damage to gastric epithelium.
- **Weight and Metabolic Regulation**: Standardized Cissus extracts, particularly in combination with other ingredients, have been studied for their ability to modulate blood glucose levels, reduce body weight, and improve lipid profiles in overweight individuals, with several human trials suggesting benefit in metabolic syndrome.
- **Anticancer Potential (Preclinical)**: Extracts have induced G1-phase cell cycle arrest and apoptosis via reactive oxygen species generation in multiple human cancer cell lines including HeLa, MCF-7, A431, and HT-29, though all evidence remains at the in vitro stage.
- **Analgesic Properties**: Traditional Zulu and Ayurvedic use for pain relief is supported by the plant's documented COX and LOX inhibition, and NF-κB suppression, which together reduce peripheral and central sensitization associated with musculoskeletal and nociceptive pain.

How It Works

The anti-inflammatory actions of Cissus quadrangularis are primarily mediated by suppression of the NF-κB pathway: ethyl acetate fractions block p65 NF-κB nuclear translocation, reducing transcription of pro-inflammatory genes including iNOS and TNFα, while simultaneously upregulating the cytoprotective enzyme heme oxygenase-1 (HO-1). The plant's stilbene constituents—resveratrol, piceatannol, and the plant-specific quadrangularin-A—further inhibit eicosanoid biosynthesis by blocking cyclooxygenase-1, cyclooxygenase-2, and 5-lipoxygenase enzymatic activity, reducing prostaglandin E2 and leukotriene B4 production. Bone healing is attributed primarily to phytosterols (β-sitosterol, ketosetosterol), which are hypothesized to interact with steroid hormone receptors on osteoblasts, promoting differentiation and matrix mineralization, while the plant's calcium, phosphorus, and ascorbic acid content supplies direct substrates for hydroxyapatite crystal formation and collagen cross-linking. Antioxidant effects are additionally mediated through the flavonoids quercetin and isorhamnetin, which donate hydrogen atoms to neutralize reactive oxygen species and chelate transition metal ions that catalyze Fenton-type oxidative reactions.

Scientific Research

The evidence base for Cissus quadrangularis consists predominantly of in vitro mechanistic studies and animal models, with a modest number of human clinical trials of variable quality conducted mainly in India and West Africa. Controlled trials examining bone fracture healing have reported accelerated radiological union and reduced pain and edema in patients receiving standardized oral extracts, with one oft-cited controlled study suggesting fracture healing time reduced by approximately one-third; however, these trials are generally small, lack rigorous blinding, and have not been independently replicated in high-income country settings. The most methodologically developed human trials have examined the plant's effects on obesity and metabolic parameters, including at least two randomized, double-blind, placebo-controlled trials (ranging from approximately 90 to 168 participants) reporting significant reductions in body weight, waist circumference, fasting glucose, and total cholesterol in overweight adults over 8–10 weeks. No large-scale, multi-center RCTs with pre-registered protocols or systematic reviews with meta-analysis currently exist for any indication, and the bone-healing evidence in particular lacks the rigor required for high-confidence clinical recommendations.

Clinical Summary

Clinical investigation of Cissus quadrangularis has centered on two primary areas: bone fracture healing and metabolic/weight management. Small controlled trials in fracture patients—primarily conducted in India and Nigeria—measured outcomes including radiological callus formation, pain visual analogue scores, and edema reduction, generally finding benefit with standardized stem extract doses of 500–1000 mg twice daily, though these studies are limited by small sample sizes (typically under 100 participants), inadequate blinding, and inconsistent extract standardization. The metabolic trials were more methodologically rigorous, with two double-blind RCTs reporting statistically significant reductions in body mass index (2–4 kg/m² over 8–10 weeks), fasting blood glucose, and LDL cholesterol in overweight adults receiving a standardized Cissus extract alone or in combination with Irvingia gabonensis. Overall confidence in the clinical evidence is low-to-moderate: results are directionally consistent with preclinical findings but require confirmation in larger, independently conducted, pre-registered trials before definitive therapeutic claims can be supported.

Nutritional Profile

The edible stems of Cissus quadrangularis are notable for their calcium and phosphorus content, which directly supports their bone-healing applications, though precise mg/g quantification varies by geographic chemotype and processing method. Vitamin C (ascorbic acid) is present in biologically meaningful quantities in fresh stem material, contributing to its antioxidant activity and its role as a cofactor for prolyl and lysyl hydroxylases in collagen biosynthesis. β-Carotene (provitamin A) is detected in leaf and stem fractions and provides additional antioxidant activity. The phytochemical fraction includes triterpenoids (friedelin, lupeol, α-amyrin, β-amyrin), phytosterols (β-sitosterol, ketosetosterol—estimated at 0.5–2% of dry extract in standardized products), flavonoids (quercetin, genistein, daidzein, isorhamnetin), and stilbene-class polyphenols (resveratrol, piceatannol, quadrangularin-A). Tannins and calcium oxalate are also present and may reduce bioavailability of certain minerals if consumed in high quantities; processing by cooking or drying significantly reduces calcium oxalate content and improves mineral bioavailability.

Preparation & Dosage

- **Dried stem powder (traditional)**: 3–6 g per day in divided doses, prepared as a decoction boiled in water for 15–20 minutes; this is the classical Zulu and Ayurvedic preparation for bone fractures and joint pain.
- **Standardized extract capsules (most studied form)**: 500–1000 mg of a standardized extract (typically standardized to ketosterones or total phytosterols) taken twice daily with meals; this form was used in the majority of published human trials.
- **Ethanol or aqueous extract**: Used in preclinical research; equivalent standardized oral extracts typically represent a 5:1 to 10:1 concentration ratio relative to raw plant material.
- **Combination products**: Frequently co-formulated with Irvingia gabonensis, glucosamine, or calcium supplements in commercial bone and joint support products; the 300 mg Cissus + Irvingia combination was used in published weight-loss RCTs.
- **Timing**: Best taken with food to reduce potential gastrointestinal discomfort and to align with meal-time calcium absorption for bone healing applications.
- **Duration**: Traditional use for fracture healing continued for 4–8 weeks; clinical trials have ranged from 8 to 10 weeks for metabolic endpoints; long-term safety beyond 3 months has not been formally established.

Synergy & Pairings

Cissus quadrangularis has been most extensively studied in combination with Irvingia gabonensis (African bush mango), where the pairing demonstrated additive effects on weight reduction, fasting glucose, and lipid normalization in a published double-blind RCT, likely due to complementary mechanisms involving adipokine regulation and gastrointestinal enzyme inhibition. For bone healing applications, co-administration with calcium and vitamin D3 is pharmacologically rational and widely practiced, as Cissus provides osteoblast-stimulating phytosterols and the anti-inflammatory scaffolding for fracture repair while exogenous calcium and vitamin D supply the mineral substrates and hormonal signaling required for hydroxyapatite deposition. The combination of Cissus with glucosamine sulfate is commonly found in joint support formulations, reflecting the complementary actions of Cissus-derived COX/LOX inhibition (addressing inflammation) and glucosamine-driven proteoglycan synthesis (addressing cartilage matrix maintenance).

Safety & Interactions

At doses used in published clinical trials (500–1000 mg standardized extract twice daily for up to 10 weeks), Cissus quadrangularis appears to be generally well tolerated, with reported adverse effects limited to mild and transient gastrointestinal symptoms including flatulence, loose stool, headache, and dry mouth, typically resolving without intervention. No serious adverse events or hepatotoxicity signals have been reported in available human trials, but the limited duration and size of existing safety data mean that long-term safety beyond 3 months is not formally established. Theoretically important drug interactions include potential additive effects with anticoagulants or antiplatelet agents given the resveratrol and quercetin content, and possible additive hypoglycemic effects with insulin or oral antidiabetic drugs given the plant's demonstrated blood glucose-lowering activity in clinical trials; patients on these medications should use Cissus extracts with medical supervision. The plant is contraindicated in pregnancy based on traditional cautions and the presence of phytoestrogenic isoflavones (genistein, daidzein) that could theoretically interfere with hormonal regulation; safety during lactation has not been evaluated, and use in these populations should be avoided until further data are available.